Observational studyCardiovascular therapeutics2026
Vasoactive-Inotropic Score Reduction Rate Is Highly Associated With Prognosis for Critically Ill Patients With Cardiogenic Shock: Insights From the Real-World Dynamic Data.
Observational study in Cardiovascular therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vaso-active inotropic scores: Clinical value, pros and cons.JHLT open · 2026Article
- Vasoactive-Inotropic Score Reduction Rate Is Highly Associated With Prognosis for Critically Ill Patients With Cardiogenic Shock: Insights From the Real-World Dynamic Data.Cardiovascular therapeutics · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In cardiogenic shock (CS), titration of both the choice and dosage of inotropes and vasopressors is crucial. The vasoactive-inotropic score (VIS) quantifies hemodynamic support, while the effect of temporal VIS change on prognosis remains unclear. This study evaluated the association between the vasoactive-inotropic score reduction rate (VRR) to measure VIS changes over time and explore its association with mortality in CS patients. Methods: We performed a retrospective observational study using two large intensive care databases (MIMIC-IV and eICU). Adult patients with CS receiving vasoactive-inotropic agents within 24 h after ICU admission were included. VIS was calculated using the updated VIS 2020, and VRR was defined to capture the relative change in VIS over time. Patients were categorized into VIS-decreasing and VIS-increasing groups. The primary outcome was in-hospital mortality; secondary outcomes were intensive care unit (ICU) and 28-day mortality (28-day mortality only for the MIMIC-IV database). Associations between VRR and outcomes were examined using four models: (1) log-rank analysis, (2) Cox model adjusted for all covariates, (3) Cox model adjusted for covariates selected by univariable analyses, and (4) Cox model adjusted for covariates selected by a random forest algorithm. Results: A total of 3170 adult CS patients were analyzed. All models in both MIMIC-IV and eICU showed that an increasing VIS over time was consistently associated with higher in-hospital, ICU, and 28-day mortality compared with a decreasing VIS in the MIMIC-IV cohort ( Conclusions: In adult CS patients, a greater reduction in VIS over time is strongly associated with lower mortality. VRR provides a simple, dynamic summary of vasoactive trajectories and may serve as a useful adjunct for risk stratification alongside other clinical and biochemical markers, although prospective validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.